ClinicalTrials.gg
CompletedNCT05208528MICRORIN_2Updated May 4, 2026

Effect of the Probiotic ES1 and Its Inactivated Form (HT-ES1) Over Symptomatology Asociated With Allergic Rhinitis

An interventional study of ES1 group and HT-ES1 group in Allergic Rhinitis, sponsored by Fundació Eurecat. Completed at 1 site in Spain. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by Fundació Eurecat · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Rhinitis, Allergic with a site in Spain — 9 open to participants now, 9 under way, 6 of them phase 3. Rhinitis, Allergic · Spain.

Enrollment
19th of 24
72 · median 145
Started
2022
the only one that year
No phase
6 of 29
2 open now
Registered
22nd of 29
by date
Lead sponsor
1 of 29
Fundació Eurecat

Among the 29 studies in Rhinitis, Allergic with a site in Spain, this one is the 19th largest by enrollment of the 24 interventional ones that give a count, is the only one that started in 2022, is one of 6 with no phase, and was the 22nd registered.

Rhinitis, Allergic

718 studies on the registry are indexed under Rhinitis, Allergic; 94 are open to participants now.

Browse Rhinitis, Allergic studies →

Open to participants now

9 of the 29 studies in Rhinitis, Allergic with a site in Spain are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 54 Rhinitis, Allergic studies recruiting now, 11 (20%) set no upper age limit and 38 (70%) stop at 75 or younger; 22 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Rhinitis, Allergic with a site in Spain, or all of them as a file.
02

Study summary

Allergic rhinitis (AR) is a health problem characterised by an inflammatory reaction in the nasal mucosa mediated by immunoglobulin (Ig) E and resulting from exposure to environmental allergens, such as pollen and dust mites.

AR symptoms can significantly affect the quality of life of patients suffering from AR, causing substantial direct health care costs and indirect costs due to absenteeism from work.

The effects of pharmacological treatments are not always fully effective and have adverse effects, resulting in a significant proportion of AR patients continuing to experience symptoms or being dissatisfied.

Considering the relationship between AR and intestinal microbiota (IM), the use of probiotics, live microorganisms that, when consumed in adequate amounts, confer beneficial effects on the host, emerges as a potential strategy to prevent or treat certain allergies. There are different mechanisms of action by which probiotics may exert their effects on the treatment or prevention of allergies through modulation of the immune system and stimulation of tolerance. Probiotics promote a change in IM. In addition, probiotics stimulate gut-associated lymphoid tissue, modulating inflammation and immune reactions present in AR, promoting a more favourable profile by increasing the production of the modulatory cytokines IL-10 and TGFβ by Treg cells. Probiotics can restore the Th1:Th2 balance by inducing Th1 responses through the production of IL-12 and interferon (IFN)-γ, or by suppressing Th2 responses through the depletion of IL-4. In addition, probiotics may exert immunomodulatory effects through stimulating mucosal IgA production.

The hypothesis of the present study is that supplementation with the probiotic Bifidobacterium longum ES1 and/or with the heat treated version of ES1 will decrease the symptomatology associated with AR and improve the quality of life of individuals by modulating IM and potentiating Treg cells and the Th1 response.

The main objective of the present study is to determine the effects of supplementation with the probiotic Bifidobacterium longum ES1 and the heat treated version of ES1 (HT-ES1) on the symptoms associated with AR.

The secondary objectives of the study are to determine the effects of the treatments over: 1) Quality of life; 2) Blood immunological markers (IFN-γ, IL-12, IL-10, TGF-β, IgE, IL-4, IL-13, IL-19 and IL-8); 3) Faecal immunological marker IgA; 4)Faecal microbiota composition.

Read the detailed description

Parallel, randomized, placebo-controlled, and double-blind intervention trial.

75 participants (25 in each group), men and women, aged between 18 and 60 years, with moderate-severe persistent AR symptoms and dust mite allergy.

The 75 study participants will be randomly divided into three groups depending on whether they receive supplementation with the probiotic Bifidobacterium longum ES1, supplementation with the heat treated version of ES1 (HT-ES1) or placebo during the 2-month study period. After the treatment period the volunteers will be followed up for one month.

During the study, patients will be able to continue using conventional drug treatment for AR, including oral and local antihistamines, oral and intranasal corticosteroids, and intranasal decongestants.

Intervention products are the probiotic Bifidobacterium longum ES1 (ES1), the heat treated version of ES1 (HT-ES1) and a placebo (maltodextrin). The delivery format of the products to the volunteers will be in capsules.

The total duration of the study will be of 92 days (13 weeks).

Each participant will perform 4 visits. The study visits will be the following:

  • a pre-selection visit to check inclusion/exclusion criteria (V0; day 1, week 1) and, in case of meeting the criteria,
  • a study start visit (V1; day 8 +/-3 days; week 2),
  • a final study visit (V2; day 64 +/- 3 days; week 10),
  • a study follow-up visit (V3; day 92 +/- 3 days; week 14).

At visits V0, V1, V2 and V3 the use of any medications, including over the counter, will be checked.

In visits V1, V2 participants must present themselves in fasting conditions of 8 hours to obtain blood. In addition, in visits V2 and V3, participants will be asked for the presence of adverse events that could be associated with the consumption or withdrawal of the study products.

The products will be given in the V1 visit so that the participants will have all the necessary treatment to carry out the 8 weeks of study with the corresponding product.

During the study and starting from visit V0 once the volunteer has been included in the study and signed the informed consent, participants will record AR symptomatology and/or the use of AR medication on a daily basis by using the CSMS questionnaire described by Pfaar O. et al. in an online format using the Microsoft Forms application. During the study, the research team will monitor compliance of the online questionnaire by the volunteer.

Volunteers will be encouraged to maintain their dietary habits and to maintain their regular practice of physical activity during the study.

Descriptive variables related to AR and demographic variables will be obtained from participants of the study by clinical history and interviewing at visit V0.

In visits V1, V2 and V3 of the study, health-related quality of life data will be obtained by means of the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) according to Juniper, E, et al.

For the collection of faeces in visits V1, V2 and V3, participants will be previously provided with a faeces collection kit (two different labelled tubes, one for metagenomic analysis and other for IgA determination will be provided).

03

Conditions studied

  • Allergic Rhinitis

Keywords

  • Probiotics
  • Intestinal Microbiota
  • Immune system
  • Inflammation
  • Postbiotics
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women between 18 and 60 years of age.
  2. Present a medical history of ARs defined according to the International Consensus on Rhinitis for at least 2 years.
  3. Present a positive IgE sensitization test to dust mite allergen during the last 5 years.

    * Participants may present various sensitizations to different allergen in addition to allergy to dust mite.

  4. Present the criteria for moderate-to-severe persistent AR phenotype according to the Allergic Rhinitis and its Impact on Asthma (ARIA) classification:

    • The intensity of signs and symptoms interferes with sleep; interferes with daily activities, sports and leisure; interferes with work activities; and symptoms present are troublesome.
    • The symptoms are present more than 4 days a week and during more than 4 consecutive weeks.
  5. Present symptomatology at the pre-selection visit. This is, present, according to ARIA criteria, 2 or more of the following symptoms during more than 1 hour a day: water rhinorrhoea; sneezing, especially paroxysmal; nasal obstruction; nasal puritis; with or without conjunctivitis.
  6. Sign the form.

Exclusion criteria

Exclusion Criteria:

  1. Age under 18 or over 60 years old.
  2. Present intolerances and/or food allergies related to the products of the study.
  3. Being pregnant or intending to become pregnant.
  4. Be in breastfeeding period.
  5. Participate in or have participated in a clinical trial or nutritional intervention study in the last 30 days prior to inclusion in the study.
  6. Present some chronic gastrointestinal disease.
  7. Clinical history of anemia.
  8. Having received antibiotic treatment up to 30 days before the start of the study.
  9. Having received immunotherapy treatment for dust mite allergen before the start of the study and during the study.
  10. Having received immunotherapy treatment for allergens other than dust mites up to 30 days before the start of the study and during the study.
  11. Taking probiotics, prebiotics and/or postbiotics up to 30 days before the start of the study and during the study.
  12. Present any disease with immune system involvement (, disease, hepatitis, cancer, etc.).
  13. Having received chemotherapy or other therapy during the previous year.
  14. Medical history of surgical procedures of nasal cavity and sinuses, recent surgery of gastrointestinal tract or bariatric surgery (ever).
  15. Being unable to follow the study guidelines.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    ES1 group

    Participants treated with Bifidobacterium longum ES1 for 2 months.

    Dietary Supplement: ES1 group

  • Experimental
    HT-ES1 group

    Participants treated with heat treated version of ES1 for 2 months.

    Dietary Supplement: HT-ES1 group

  • Placebo comparator
    Control group

    Participants treated with maltodextrin for 2 months.

    Dietary Supplement: Control group

Interventions

  • Dietary supplementES1 group

    Participants will intake 2 capsules of Bifidobacterium longum ES1 (2E09 CFU of probiotic/day with maltodextrin as excipient).

  • Dietary supplementHT-ES1 group

    Participants will intake 2 capsules of HT-ES1 (2E09 cells/day equivalent to 20 mg/day when prepared from a postbiotic batch at a concentration of 1E11 cells/g with maltodextrin as excipient).

  • Dietary supplementControl group

    Participants will intake 2 capsules/day, with 250 mg maltodextrin/capsule.

06

What researchers measure

Primary outcomes

  1. Combined Symptoms and Medication Score

    Participants will complete the Combined Symptoms and Medication Score (CSMS) questionnaire daily in an online form. The CSMS questionnaire takes into account the severity of symptoms and the use of rescue medication to asses the efficacy of treatments for AR. The CSMS is the sum of daily symptom score (dSS) and the daily medication score (dMS) and has a range of 0 to 6. The mean CSMS will be calculated weekly for each study period, that is the basal period (first week until V1); the treatment period (period between V1 and V2 visits) and the follow-up period (period between V2 and V3 visits), from the sum of all daily CSMS during each week of the study and divided by the number of days of each week of the study.

    Time frame: Daily for the thirteen weeks of the study.

Secondary outcomes

  1. Nasal and conjunctival symptoms (dSS)

    The CSMS is the sum of the daily symptom score (dSS) and the daily medication score (dMS). The dSS is composed of 6 individual symptom scores: 4 nasal symptoms and 2 ocular symptoms, all rated on a scale of 0 to 3. The dSS is calculated as the mean of all daily dSS (range 0-18) and divided by the number of individual symptoms (6 symptoms). Therefore, the mean dSS can range from 0 to 3. The mean dSS will be calculated weekly for each study period, that is the basal period (first week until V1); the treatment period (period between V1 and V2 visits) and the follow-up period (period between V2 and V3 visits), from the sum of all daily CSMS during each week of the study and divided by the number of days of each week of the study.

    Time frame: Daily for the thirteen weeks of the study.

  2. Nasal symptoms.

    4 nasal symptoms: itchy nose, sneezing, runny nose and stuffy nose. All nasal symptoms rated on a scale of 0 to 3. The Nasal symptoms is calculated as the mean of all daily nasal symptoms (range 0-12) and divided by the number of individual nasal symptoms (4 symptoms). Therefore, the mean Nasal symptoms can range from 0 to 3, being higher scores related to worse symptoms. The mean Nasal symptoms will be calculated weekly for each study period, that is the basal period (first week until V1); the treatment period (period between V1 and V2 visits) and the follow-up period (period between V2 and V3 visits), from the sum of all daily CSMS during each week of the study and divided by the number of days of each week of the study.

    Time frame: Daily for the thirteen weeks of the study.

  3. Conjunctival symptoms

    2 ocular symptoms: itchy/red eyes and watery eyes. All conjunctival symptoms rated on a scale of 0 to 3. The conjunctival symptoms is calculated as the mean of all daily conjunctival symptoms (range 0-6) and divided by the number of individual conjunctival symptoms (2 symptoms). Therefore, the mean conjunctival symptoms can range from 0 to 3, being higher scores related to worse symptoms. The mean conjunctival symptoms will be calculated weekly for each study period, that is the basal period (first week until V1); the treatment period (period between V1 and V2 visits) and the follow-up period (period between V2 and V3 visits), from the sum of all daily CSMS during each week of the study and divided by the number of days of each week of the study.

    Time frame: Daily for the thirteen weeks of the study.

  4. Use of rescue medication.

    The daily medication score (dMS) is based on the following scores: 0, no rescue medication; 1, oral and/or topical nonsedative H1 antihistamines (H1A); 2, Intranasal corticosteroids (INS) with/without H1A; and 3, oral corticosteroids with/without INS, with/without H1A.

    Time frame: Daily for the thirteen weeks of the study.

  5. Number of days without medication.

    From CSMS questionnaire the number of days without rescue medication is quantified for each period of the study.

    Time frame: Daily for the thirteen weeks of the study.

  6. Use of other medications for AR.

    Participants will record daily the use of other treatments for AR different that the medications described in the CSMS questionnaire using the online questionnaire.

    Time frame: Daily for the thirteen weeks of the study.

  7. Change in experienced troublesome functional impairments.

    Quality of life will be estimated through Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ). The RQLQ is a validated questionnaire which has 28 questions in seven domains (sleep, non-rhinoconjunctivitis symptoms, practical problems, nasal symptoms, eye symptoms, activity limitations, and emotional function). Patients are asked to recall impairments experienced during the previous week and to respond to each item on a 7-point scale (0 = no impairment; 6 = maximum impairment). The overall RQLQ score is the mean of all 28 responses and higher scores reflect lower quality of life.

    Time frame: At week 2, week 10 and week 14.

  8. Change in serum IL-10 levels.

    Serum IL-10 levels will be measured by human ELISA kits.

    Time frame: At week 2 and week 10.

  9. Change in serum TGF-β levels.

    Serum TGF-β levels will be measured by human ELISA kits.

    Time frame: At week 2 and week 10.

  10. Change in serum IL-12 levels.

    Serum IL-12 levels will be measured by human ELISA kits.

    Time frame: At week 2 and week 10.

  11. Change in serum IFN-γ levels.

    Serum IFN-γ levels will be measured by human ELISA kits.

    Time frame: At week 2 and week 10.

  12. Change in serum IgE levels.

    Serum IgE levels will be measured by human ELISA kits.

    Time frame: At week 2 and week 10.

  13. Change in serum IL-4 levels.

    Serum IL-4 levels will be measured by human ELISA kits.

    Time frame: At week 2 and week 10.

  14. Change in serum IL-13 levels.

    Serum IL-13 levels will be measured by human ELISA kits.

    Time frame: At week 2 and week 10.

  15. Change in serum IL-8 levels.

    Serum IL-8 levels will be measured by human ELISA kits.

    Time frame: At week 2 and week 10.

  16. Change in serum IL-19 levels.

    Serum IL-19 levels will be measured by human ELISA kits.

    Time frame: At week 2 and week 10.

  17. Change in stool IgA levels.

    Stool IL-19 levels will be measured by human ELISA kits.

    Time frame: At week 2, week 10 and week 14.

  18. Metagenomic analysis.

    Total DNA extracted from stool samples will be sequenced on an Illumina platform. It will be analysed the taxonomic profile, toxin-producing genes, bacterial functions and presence of pathogens.

    Time frame: At week 2, week 10 and week 14.

07

Study locations

1 site
  • Eurecat
    Reus, Reus 43204, Spain
08

References and documents

Publications

  • Cardoso A, Naghibi M, Climent E, Rodenes-Gavidia A, Lamelas A, Llobregat L, Martinez-Blanch J, Friedman D, Vijayakumar V, Day R. Effects of Live and Heat-Treated Bifidobacterium longum CECT 7347 in Adults With Allergic Rhinitis: A Randomised, Double-Blind, Placebo-Controlled Trial. Allergy. 2026 Apr 28. doi: 10.1111/all.70360. Online ahead of print. PubMed 42047238 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in Jan 2024, 23 months.

Of 66 non-industry interventional studies with no phase under Rhinitis, Allergic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 28. This study's 23 months is above that.

Counting every sponsor, half of 87 studies reached it within 11 months; a quarter within 4 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2022
First posted
Jan 26, 2022
StartActual
Jan 23, 2022
Primary completionActual
Jan 17, 2024
CompletionActual
Mar 27, 2024
Last update
May 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05208528
Lead sponsor
Fundació Eurecat
Collaborators
ADM-BIOPOLIS S.L.
Responsible party
Sponsor
First posted
Jan 26, 2022
Start date
Jan 23, 2022
Primary completion
Jan 17, 2024
Completion
Mar 27, 2024
Last update
May 4, 2026

Study contacts

Josep M Del Bas, PhD
principal investigator · UTNS (Eurecat-Reus)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion